Caraco Pharmaceutical Laboratories, Ltd.

FDA approval granted for Citalopram Hydrobromide tablets

Published in FDA Law Weekly, December 16th, 2004

Caraco Pharmaceutical Laboratories, Ltd., (CPD) has received approval from the U.S. Food and Drug Administration (FDA) for Citalopram Hydrobromide tablets, 10 mg, 20 mg and 40 mg, Jitendra N. Doshi, CEO, announced.

This product is the generic equivalent of Celexa, a product marketed by Forest Labs, for the treatment of depression with annual brand sales of approximately $1.4 billion.

The product launch will commence immediately.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures and distributes generic and private-label prescription drugs to wholesalers, distributors, drugstore chains, healthcare...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of FDA Law Weekly

Source: FDA Law Weekly (2004-12-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry